NASDAQ:HCM - HUTCHISON CHINA/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.90 -0.07 (-0.26 %) (As of 05/23/2019 03:19 PM ET)Previous Close$26.97Today's Range$26.50 - $27.0752-Week Range$20.83 - $39.68Volume4,890 shsAverage Volume113,540 shsMarket Capitalization$3.59 billionP/E RatioN/ADividend YieldN/ABeta1.04 ProfileAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited. Receive HCM News and Ratings via Email Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HCM Previous Symbol CUSIPN/A CIK1648257 Webhttp://www.chi-med.com/ Phone852-2128-1188Debt Debt-to-Equity Ratio0.06 Current Ratio4.33 Quick Ratio4.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$214.11 million Price / Sales16.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book8.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees714 Outstanding Shares133,320,000Market Cap$3.59 billion Next Earnings DateN/A OptionableNot Optionable HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions What is HUTCHISON CHINA/S's stock symbol? HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM." What price target have analysts set for HCM? 2 equities research analysts have issued 1-year target prices for HUTCHISON CHINA/S's shares. Their forecasts range from $26.82 to $26.82. On average, they expect HUTCHISON CHINA/S's share price to reach $26.82 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for HUTCHISON CHINA/S. What is the consensus analysts' recommendation for HUTCHISON CHINA/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHISON CHINA/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HUTCHISON CHINA/S. Has HUTCHISON CHINA/S been receiving favorable news coverage? News stories about HCM stock have trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. HUTCHISON CHINA/S earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the stock's share price in the near future. Who are some of HUTCHISON CHINA/S's key competitors? Some companies that are related to HUTCHISON CHINA/S include GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA) and Perrigo (PRGO). What other stocks do shareholders of HUTCHISON CHINA/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHISON CHINA/S investors own include Telford Homes (TEF), Premier Oil (PMO), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), AbbVie (ABBV), Weyerhaeuser (WY), Inland Homes (INL) and Madrigal Pharmaceuticals (MDGL). Who are HUTCHISON CHINA/S's key executives? HUTCHISON CHINA/S's management team includes the folowing people: Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 67)Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 53)Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 52)Dr. Weiguo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67) When did HUTCHISON CHINA/S IPO? (HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHISON CHINA/S's major shareholders? HUTCHISON CHINA/S's stock is owned by many different of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (3.16%), BlackRock Inc. (2.57%), BNP Paribas Arbitrage SA (1.55%), JPMorgan Chase & Co. (0.50%), Wellington Management Group LLP (0.37%) and Sumitomo Mitsui Trust Holdings Inc. (0.33%). Which institutional investors are selling HUTCHISON CHINA/S stock? HCM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, OppenheimerFunds Inc., Caisse DE Depot ET Placement DU Quebec, Goldman Sachs Group Inc., Renaissance Technologies LLC, Morgan Stanley, First Trust Advisors LP and Mckinley Capital Management LLC Delaware. Which institutional investors are buying HUTCHISON CHINA/S stock? HCM stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, BlackRock Inc., Hsbc Holdings PLC, Parametric Portfolio Associates LLC, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Northern Trust Corp and Baillie Gifford & Co.. How do I buy shares of HUTCHISON CHINA/S? Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is HUTCHISON CHINA/S's stock price today? One share of HCM stock can currently be purchased for approximately $26.93. How big of a company is HUTCHISON CHINA/S? HUTCHISON CHINA/S has a market capitalization of $3.59 billion and generates $214.11 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. HUTCHISON CHINA/S employs 714 workers across the globe. What is HUTCHISON CHINA/S's official website? The official website for HUTCHISON CHINA/S is http://www.chi-med.com/. How can I contact HUTCHISON CHINA/S? HUTCHISON CHINA/S's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2128-1188 or via email at [email protected] MarketBeat Community Rating for HUTCHISON CHINA/S (NASDAQ HCM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 213 (Vote Outperform)Underperform Votes: 183 (Vote Underperform)Total Votes: 396MarketBeat's community ratings are surveys of what our community members think about HUTCHISON CHINA/S and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Diluted Earnings Per Share Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.